Alterity Therapeutics Announced That The Last Patient In The ATH434-201 Phase 2 Trial, A Randomized, Double-blind, Placebo-controlled Investigation In Early-stage Multiple System Atrophy, Has Completed The Study And Topline Results Are Expected To Be...

Alterity therapeutics宣佈，ATH434-201二期試驗的最後一名患者已完成研究，該試驗是一項針對早期多系統萎縮的隨機、雙盲、安慰劑對照研究，頂線結果預計將於...

Benzinga · 2024/12/04 23:44

Alterity Therapeutics Announced That The Last Patient In The ATH434-201 Phase 2 Trial, A Randomized, Double-blind, Placebo-controlled Investigation In Early-stage Multiple System Atrophy, Has Completed The Study And Topline Results Are Expected To Be Reported In Late January Or Early February 2025

Alterity therapeutics宣佈，ATH434-201 II期試驗的最後一位患者，這項針對早期多系統萎縮的隨機、雙盲、安慰劑對照研究，已完成研究，預計將在2025年1月底或2月初公佈初步結果。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。